Generic Medicine Info
Indications and Dosage
Head pediculosis
Adult: As 0.5% lotion: Apply sufficient amount to dry hair, allow to dry naturally, then shampoo and rinse after 8-12 hours. May repeat application, after 7-9 days, if lice is still present.
Child: ≥6 years Same as adult dose.
Special Precautions
Childn. Pregnancy and lactation.
Adverse Reactions
Dermatologic: Irritation of skin and scalp, burn and stinging sensation, dry hair, transient increase in dandruff.
Patient Counseling Information
Avoid hair exposure to open flames or other heat sources.
Monitoring Parameters
Monitor for severe skin irritation.
Description: Malathion is an organophosphate insecticide which acts as a pediculicide by inhibiting cholinesterase activity in Pediculus humanus var. capitis (head lice), resulting in rapid and massive muscle paralysis and death. It has also ovicidal activity against nits (eggs) that prevents final hatching of the nymph.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Malathion, CID=4004, (accessed on Jan. 21, 2020)

Store between 20-25°C. Protect from heat and open flames.
MIMS Class
Topical Antifungals & Antiparasites
ATC Classification
P03AX03 - malathion ; Belongs to the class of other ectoparasiticides including scabicides.
Anon. Malathion. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 06/07/2017.

Buckingham R (ed). Malathion. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 06/07/2017.

Joint Formulary Committee. Malathion. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 06/07/2017.

Malathion Lotion (Suven Life Sciences Limited). DailyMed. Source: U.S. National Library of Medicine. Accessed 06/07/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Malathion (Topical). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 06/07/2017.

Disclaimer: This information is independently developed by MIMS based on Malathion from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in